Dr. Wilky is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
12401 E 17th Ave
Aurora, CO 80045Phone+1 720-848-4289Fax+1 720-848-4293
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2009 - 2012- Johns Hopkins UniversityResidency, Internal Medicine, 2006 - 2009
Rutgers Robert Wood Johnson Medical SchoolClass of 2006
Certifications & Licensure
CO State Medical License 2018 - 2025
FL State Medical License 2013 - 2019
MD State Medical License 2009 - 2013- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Young Investigator Award ASCO/Conquer Cancer Foundation, 2012
- Alpha Omega Alpha, Medical Honor Society 2004
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Clinical Trials
- Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas Start of enrollment: 2016 Apr 19
- AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Subjects With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy Start of enrollment: 2016 Apr 01
- Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer Start of enrollment: 2017 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 38 citationsPericytoma With t(7;12) and ACTB-GLI1 Fusion: Reevaluation of an Unusual Entity and its Relationship to the Spectrum of GLI1 Fusion-related Neoplasms.Darcy A. Kerr, Andre Pinto, Ty K. Subhawong, Breelyn A. Wilky, Matthew Schlumbrecht
The American Journal of Surgical Pathology. 2019-12-01 - 108 citationsUltra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entitiesSilvia Stacchiotti, Anna Maria Frezza, Jean-Yves Blay, Elizabeth H. Baldini, Sylvie Bonvalot
Cancer. 2021-08-15 - 6 citationsBotensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial.Andrea J Bullock, Benjamin L Schlechter, Marwan G Fakih, Apostolia M Tsimberidou, Joseph E Grossman
Nature Medicine. 2024-09-01
Lectures
- Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 bloc...2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
- A phase II trial of axitinib plus pembrolizumab for patients with advanced alveolar soft part sarcoma (ASPS) and other soft tissue sarcomas (STS).2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Other
- Complete BibliographyWilky BA
http://www.ncbi.nlm.nih.gov/sites/myncbi/1VYg-8UHXVF5x/bibliography/48190547/public/?sort=date&direction=ascending
Press Mentions
Agenus (AGEN) Q1 2023 Earnings Call TranscriptMay 9th, 2023- Agenus Inc (AGEN) Q2 2020 Earnings Call TranscriptAugust 6th, 2020
Deciphera Pharmaceuticals, Inc. To Present Data from DCC-3014 and Ripretinib Programs at the Connective Tissue Oncology Society (CTOS) 2019 Annual MeetingNovember 13th, 2019- Join now to see all
Professional Memberships
- Member
- Member
- Member
- Member
- Connective Tissue Oncology SocietyMember
- Children's Oncology GroupMember
- Sarcoma Alliance for Research through Collaboration (SARC)Member
External Links
- Sarcoma Programhttp://sylvester.org/cancer/bone-and-soft-tissue
- Linked Inhttps://www.linkedin.com/pub/breelyn-wilky-md/55/2a/0
- Bloghttp://breelynwilkymd.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
